Opinion
Orthocell's 92 US Units in October Show Slow Medtech Climb
The nerve repair maker's best US month since launch produced AU$279,000 in revenue, a reminder of how long hospital access takes to convert into sales.
Orthocell Limited
Opinion
The nerve repair maker's best US month since launch produced AU$279,000 in revenue, a reminder of how long hospital access takes to convert into sales.